My Profile

Search abstracts

Lewis Sheiner


2019
Stockholm, Sweden



2018
Montreux, Switzerland

2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 20 (2011) Abstr 2122 [www.page-meeting.org/?abstract=2122]


PDF poster/presentation:
Click to open Click to open

Poster: Absorption and physiology-based PK


IV-65 Kirill Zhudenkov Pharmacokinetics of PEG-IFN Alpha in HCV Infected Patients

K. Zhudenkov (1), S. Vinogradova (2), T. Karelina (1,2)

(1) Institute for Systems Biology SPb, Moscow, Russia; (2) Moscow State University, Moscow, Russia

Objectives: To investigate PK of PEG-IFN Alpha in HCV infected patients using population modeling and to compare two software packages - NONMEM 7 and Monolix 3.2. Previously the PK of PEG-IFN was studied in [1] without using a population modeling approach. However, data available from [1] suggested application of such methods with the aim of getting more details on the PK of  PEG-IFN.

Methods: We modeled the plasma concentrations of PEG-IFN collected in 24 patients on two occasions (after 0'th and 7'th day of treatment). Also a variety of covariate data for each patient (race, level of inflammation, level of CD4+ cells, level of alanine aminotransferase (ALT), level of response - sustained virological responders (SVRs) and nonresponders (NRs)) [1] was available. All ODE models built were tested with NONMEM 7 running FOCE with INTERACTION algorithm and with Monolix 3.2 running SAEM algorithm.

The first step of building a model was to choose a basic structural model - estimate number of compartments, model of absorption, check for saturation in absorption and elimination. Further model building implied estimation of inter-individual variability (IIV) for structure model parameters. After IIV estimation we selected the best error model. Further model verification included covariate analysis - building transformations of parameters with IIV for continuous covariates or analysis of different groups of parameters using categorical covariates or even analysis of categorical variability of parameters with IIV using categorical covariates.

Results: The model selection was similar using either NONMEM or MONOLIX. The final PK structural model contained one compartment with first order absorption and linear elimination. IIV analysis showed the necessity of application of IIV to volume V and absorption Ka.  Analysis using categorical and continuous covariates showed no significant correlations (all correlation coefficients showed to be between -0.5 and 0.5) between means of parameters with IIV and covariates. In contrast, categorical variabilities for V from level of response and for Ka from race were apparent. Further analysis showed that such variabilities did not lead to significant lowering of OFV in NONMEM and -2xLL in Monolix.

Conclusions: Final structural model gave the values for V, Ka and Ke parameters (1.08 L/kg, 1.32 1/day and 0.41 1/day respectively) close to values obtained by Andrew H. Talal et al [1]. IIV for V and Ka parameters (0.298 and 0.89 respectively) allowed the data to be more accurately described. No difference between pharmacokinetic parameters for Responders and Non-responders was revealed by population analysis.

References:
[1] Andrew H. Talal Pharmacodynamics of PEG-IFN Alpha Differentiate HIV/HCV Coinfected Sustained Virological Responders From Nonresponders. HEPATOLOGY 2006; 43:943-953.